SecBot SecBot
8-K ·Filed May 1, 2026

ARVN

ARVINAS, INC.
BULLISH
Impact 8/10
Horizonimmediate Processed6mo ago SEC0001628280-26-029210
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The FDA approval is a major value inflection point for Arvinas, likely driving a significant positive stock reaction. Monitor for the selection of a third-party commercialization partner and initial launch metrics. The $50M milestone provides near-term cash, but long-term value depends on commercial uptake and label expansion.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$10.51
T+0 close · May 1, 2026 · via day close
Latest settled
−21.98%
T+60 · $8.20
Vs SPY
−25.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $10.51entry
  2. T+1 · 7mo ago +2.57%α +2.91% · $10.78
  3. T+5 · 6mo ago −3.04%α −5.39% · $10.19
  4. T+20 · 6mo ago −18.36%α −23.65% · $8.58
  5. T+60 · 4mo ago −21.98%α −25.05% · $8.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arvinas announced FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced breast cancer, the first-ever approved PROTAC therapy. The approval came ahead of the June 5 PDUFA date, and Arvinas will receive a $50M milestone payment from partner Pfizer. This transformative milestone validates the PROTAC platform and provides a new treatment option in a high-need setting.

Key Facts

  • FDA approved VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after prior endocrine therapy.
  • First-and-only FDA-approved PROTAC (protein degrader) therapy.
  • Approval received ahead of the June 5, 2026 PDUFA date.
  • In the Phase 3 VERITAC-2 trial, VEPPANU reduced risk of disease progression or death by 43% vs fulvestrant (HR 0.57, p=0.0001) in ESR1-mutated patients.
  • Arvinas will receive a $50M development milestone payment from Pfizer, offset by amounts owed to Yale University.
  • Arvinas and Pfizer remain on track to select a third-party commercial partner.

Financial Impact

$50 million milestone payment from Pfizer (net of Yale obligations); future commercial revenue potential for a first-in-class drug

revenuecash flowpipeline value

Risk Factors

  • Commercial execution risk given Arvinas and Pfizer are outsourcing commercialization
  • Potential safety concerns (QT prolongation, liver enzyme elevations) may limit use
  • Competition from other CDK4/6 inhibitor combinations and emerging therapies
  • ESR1-mutant patient population limits addressable market (~40-50% of ER+ patients)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-029210
Document: fdaapprovalpressrelease_.htm0001628280-26-029210
Document: 0001628280-26-029210-index-headers.html0001628280-26-029210
Document: 0001628280-26-029210-index.html0001628280-26-029210
Document: 0001628280-26-029210.txt0001628280-26-029210

Track record

21 reports on ARVN

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 1, 2026